Grant of Options and PDMR notification

RNS Number : 6510L
Oncimmune Holdings PLC
01 May 2020
 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Grant of Options and PDMR notification

 

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening,  detection and care of cancer, today announces t hat options to subscribe for an aggregate 546,052 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted to Matthew Luttrell, Chief Commercial Officer, Tariq Sethi, Chief Scientific Officer, and Ron Kirschner, General Counsel & Company Secretary as follows:

 

Name

Position

Number of Share Options Awarded

Exercise Price per Share

Matthew Luttrell

Chief Commercial Officer

223,684

£0.76

Tariq Sethi

Chief Scientific Officer

92,105

£0.76

Ron Kirschner

General Counsel & Company Secretary

230,263

£0.76

 

The Options have been granted under the 2016 Share Option Plan and have an exercise price of £0.76, being the closing price of shares at 30 April 2020.  

 

Other than the grant of the Options, none of Mr Luttrell, Mr Sethi or Mr Kirschner or their respective connected persons have any beneficial interest in the Ordinary Shares of the Company.

 

This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

1)  Matthew Luttrell

2)  Tariq Sethi

3)  Ron Kirschner

2

 

Reason for the notification

 

a)

 

Position/status

 

 

1)  Chief Commercial Officer

2)  Chief Scientific Officer

3)  General Counsel & Company Secretary

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Oncimmune Holdings plc

b)

 

LEI

 

 

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




1) £0.76

223,684




2) £0.76

92,105




3) £0.76

230,263







d)

 

Aggregated information




- Aggregated volume

546,052 



- Price

£414,999.52



e)

 

Date of the transaction

 

 

1 May 2020

f)

 

Place of the transaction

 

 

Outside a trading venue

 

For further information:

Oncimmune Holdings plc

Ron Kirschner, General Counsel & Company Secretary

contact@oncimmune.co.uk

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHUPUBPAUPUUBG
UK 100

Latest directors dealings